Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of DiseaseGabriella Fabbrocini, Giuseppe Argenziano, Luca Stingeni et al.|Dermatology|2021Cited by 18
Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective studyMartina Dragotto, Emanuele Trovato, Eugenio Capalbo et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 8
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areasAngela Michelucci, M. Romanelli, Flavia Manzo Margiotta et al.|Archives of Dermatological Research|2024Cited by 5
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observationFlavia Manzo Margiotta, Francesca Prignano, Alessandra Michelucci et al.|Italian Journal of Dermatology and Venereology|2023Cited by 4
Risankizumab in Oncologic Patients With Psoriasis: A Case SeriesMichela Magnano, Francesca Prignano, Susanna Rossari et al.|JEADV Clinical Practice|2024Cited by 3